by stemedica admin | Sep 13, 2017 | Publications
Background: We previously reported that functional recovery of rats with spinal cord contusions can occur after acute transplantation of neural stem cells distal to the site of injury. To investigate the effects of timing of administration of human neural stem cell...
by stemedica admin | Feb 23, 2017 | Publications
Abstract Rationale: Virtually all mesenchymal stem cell (MSC) studies assume therapeutic effects accrue from local myocardial effects of engrafted MSCs. Since few intravenously-administered MSCs engraft in the myocardium, studies have mainly utilized direct myocardial...
by stemedica admin | Feb 8, 2017 | Publications
Abstract Alzheimer’s disease is the most common form of dementia in the western world, however there is no cure available for this devastating neurodegenerative disorder. Despite clinical and experimental evidence implicating the intestinal microbiota in a number of...
by stemedica admin | Jul 27, 2016 | Clinical Trials
Initial Sites Are Emory University and University of California, Irvine SAN DIEGO, California, and Lausanne, Switzerland — July 27, 2016 — Stemedica Cell Technologies, Inc. and its subsidiary, Stemedica International S.A., a leader in the development of innovative...
by stemedica admin | May 18, 2016 | Clinical Trials
Clinical trial to study the effects of Stemedica’s proprietary mesenchymal stem cells in patients with traumatic brain injury SAN DIEGO, California – May 18, 2016. Stemedica Cell Technologies, Inc. (Stemedica) received an FDA investigational new drug (IND)...
